Quantitative analysis of the interaction between the envelope protein domains and the core protein of human hepatitis B virus

Choi, Kyoung‐Jae; Lim, Chun Woo; Yoon, Mi Young; Ahn, Byung Yoon; Yu, Yeon Gyu

doi:10.1016/j.bbrc.2004.05.083

Cited by 8 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that dominant negative core protein mutants, which could not support pregenomic RNA packaging and genome maturation, could effectively inhibit replication of HBV [11]. The envelopment of virus particles was interrelated to the interactions between HBV surface proteins and core proteins, and blocking these interactions may serve as a novel anti-HBV strategy [12,13]. Two promising anti-HBV drug candidates KKJ00626 and KSG00011 (Figure 1), were found to inhibit the production of HBV particles in Huh-7 cells transfected with HBV DNA by blocking the interactions between HBV surface proteins and core proteins [14].…”

Section: Novel Targets and Related Drugsmentioning

confidence: 99%

A Review of Novel Non-Nucleoside Anti-HBV Agents and Their Mechanism of Action

Liu¹,

Li²

2016

Med chem (Los Angeles)

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a serious worldwide health problem as drugs (such as lamivudine and adefovir) for treating HBV are still unsatisfactory, due to high recurrence, drug resistance and inevitable side effects. Therefore, there exists a significant medical need to explore novel classes of drugs with different antiviral targets and mechanisms for anti-HBV purposes. Recently, some non-nucleoside HBV inhibitors with specific targets have been obtained from natural sources or prepared by synthesis. These compounds provide useful information for developing novel non-nucleoside compounds as anti-HBV agents.

show abstract

Section: Novel Targets and Related Drugsmentioning

confidence: 99%

A Review of Novel Non-Nucleoside Anti-HBV Agents and Their Mechanism of Action

Liu¹,

Li²

2016

Med chem (Los Angeles)

View full text Add to dashboard Cite

show abstract

Section: Anti‐hbv Drug Candidates: Synthetic Small Moleculesmentioning

confidence: 99%

“…Specific interactions between HBV surface proteins and core proteins are critical for the envelopment of virus particles; thus, blocking these interactions may serve as a novel anti-HBV strategy [122,123]. Asif-Ullah et al identified two small molecules, KKJ00626 and KSG00011, which blocked the interactions between HBV surface proteins and core proteins [124].…”

Section: Kkj00626/ksg00011mentioning

confidence: 99%

Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors

Qiu

Chen

2013

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

There are approximately 350 million hepatitis B virus (HBV) carriers worldwide. Chronic HBV infection increases the risk of liver cirrhosis and hepatocellular carcinoma. To date, two classes of antiviral drugs have been approved by the Food and Drug Administration for the treatment of hepatitis B, immunomodulators (interferon [IFN]-α and pegylated-interferon [PEG-IFN]-α) and nucleos(t)ide analogs (lamivudine, telbivudine, adefovir, tenofovir [TDF], and entecavir [ETV]). Of these, ETV, TDF, and PEG-IFN-α are the most effective and are currently recommended for anti-HBV therapy. However, these therapies are less than optimal because of their low rate of viral DNA and surface antigen clearance; thus, there exists a significant unmet medical need for safe and efficacious new anti-HBV drugs. Covering diverse chemical structures and mechanisms of action, non-nucleos(t)ide compounds offer great promise in the search for new anti-HBV drugs. This review summarizes the currently approved anti-HBV drugs and highlights advances in the identification and characterization of novel small molecule HBV inhibitors. We discuss the sources, structures, anti-HBV effects, mechanisms of action, and potential toxicities of these novel inhibitors.

show abstract

Survey of the year 2004 commercial optical biosensor literature

Rich

Myszka

2005

J of Molecular Recognition

115

View full text Add to dashboard Cite

The year 2004 represents a milestone for the biosensor research community: in this year, over 1000 articles were published describing experiments performed using commercially available systems. The 1038 papers we found represent a $ 10% increase over the past year and demonstrate that the implementation of biosensors continues to expand at a healthy pace. We evaluated the data presented in each paper and compiled a 'top 10' list. These 10 articles, which we recommend every biosensor user reads, describe wellperformed kinetic, equilibrium and qualitative/screening studies, provide comparisons between binding parameters obtained from different biosensor users, as well as from biosensor-and solution-based interaction analyses, and summarize the cutting-edge applications of the technology. We also re-iterate some of the experimental pitfalls that lead to sub-optimal data and over-interpreted results. We are hopeful that the biosensor community, by applying the hints we outline, will obtain data on a par with that presented in the 10 spotlighted articles. This will ensure that the scientific community at large can be confident in the data we report from optical biosensors.

show abstract

Quantitative analysis of the interaction between the envelope protein domains and the core protein of human hepatitis B virus

Cited by 8 publications

References 25 publications

A Review of Novel Non-Nucleoside Anti-HBV Agents and Their Mechanism of Action

A Review of Novel Non-Nucleoside Anti-HBV Agents and Their Mechanism of Action

Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors

Survey of the year 2004 commercial optical biosensor literature

Contact Info

Product

Resources

About